We relentlessly build on our expertise in cancer immunology and

leading-edge technologies in pursuit of transformative treatments

for cancer patients.

In Virtue of scientific research and clinical resources in China and Germany, LintonPharm has the ability to systematically build up and enrich the pipelines by relying on the clinically validated bispecific antibody platform. With the guidance of actual clinical needs, LintonPharm can flexibly choose the murine/humanized platform, and select the innovative targets to build the first-in-class bispecific antibody pipeline from the perspective of translational medicine, and select the validated targets to build the best-in-class bispecific antibody pipeline from the perspective of approved or clinically validated products.

BLA

LP000

Catumaxomab

Phase Ⅲ

Phase Ⅰ

Phase Ⅱ

Pre-clinical

IND

Indication